Reporting for the family-office world.

Join the Family Office Networks’ Webinar Series featuring Soligenix, Inc. Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. A Public Health Solutions business segment, funded entirely by the US Government to the amount of approximately $70 million to date, developing vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, emerging and antibiotic resistant infectious disease, and viral disease including Ebola, Marburg and COVID-19. Nasdaq: SNGX Stock Snapshot as of 01/22/21 Market Cap: ~ $61 Million Stock Price: $1.72 Avg Daily Vol (50D): ~ 2.3 Million Shares Outstanding: ~ 35.5 Million

Join the Family Office Networks’ Webinar Series featuring Psy Therapeutics, Inc. PSY Therapeutics, Inc. is an emerging biopharmaceutical company focused on developing transformative medicines to treat serious neurodegenerative and neuropsychiatric disorders. The Company’s novel approach to customized small molecule drug discovery and development combines cutting-edge technology with an extensive network of collaborators to drive R&D innovation and productivity. In this webinar, the PSY team will focus on their unique tau program for disease-modifying treatment of Alzheimer’s Disease (AD) and related tauopathies. They will take a deeper look at the growing patient population, assess lessons learned from other AD program failures and detail Psy’s opportunity for a new approach to disease treatment.

Join the Family Office Networks Webinar Series featuring 12/12 Ventures’ Managing Partner, Matt Barron; co-founded by Cookies’ CEO and Founder, Berner. 12/12 Ventures focuses its investment strategy on Cookies and the Cookies ecosystem: brands and businesses under the Cookies Family umbrella. Cookies is an internationally recognized cannabis lifestyle brand lauded for its premium quality and innovative genetics. Cookies is currently in production in 18 US states and 4 countries (with a 5th, Holland, in the pipeline). Cookies maintains an asset-light and capital efficient business model that is unique within the industry. Revenues increased by 850% from 2019 to 2020 and the business has scaled from 2 dispensaries at the beginning of 2019 to 26 today (with an additional 25+ scheduled to open this year alone). 12/12 is proud to finance Cookies’ continued growth and looks forward to discussing investment opportunities with the FON group.

Join the Family Office Networks Webinar series featuring Weild & Co. David Weild IV will be presenting and is known for his position as vice Chairman of NASDAQ, Head of Corporate Finance at Prudential Securities and as the “Father of the JOBS Act.” Weild & Co.’s objective is to become the world’s dominant decentralized investment bank and fill the unmet need for a large-scale investment banking platform serving the middle market. Weild & Co. now supports 100 professionals in 17 states and will soon be registered in all 50 states with its high-payout, capital efficient, work-anywhere model. The Firm attracts entrepreneurially minded investment bankers who value collaboration and are intent on contributing to social impact and the growth economy.